• AMPK’s Dual Role in Autophagy and Energy Stress Redefined

  2026-05-20

  This study overturns the prevailing model of AMPK as a direct inducer of autophagy, revealing that AMPK actually inhibits ULK1-mediated autophagy initiation during energy stress. Instead, AMPK preserves the autophagy machinery for later activation, refining our understanding of cellular adaptation to metabolic challenges and informing the design of future metabolism-focused experiments.

• BFH772 (VEGFR2 Inhibitor): Technical Guidance & Workflow Par

  2026-05-20

  BFH772 is a highly selective VEGFR2 inhibitor intended for precise modulation of VEGFR2-driven angiogenesis, particularly in tumor angiogenesis models. It should not be used in protocols requiring water solubility or broad-spectrum kinase inhibition, but is well-suited for workflows prioritizing kinase selectivity and compatibility with organic solvents.

• TG003 Cdc2-like Kinase Inhibitor: Selectivity & Splicing Con

  2026-05-19

  TG003 is a potent, selective Cdc2-like kinase (Clk) inhibitor that modulates alternative splicing by suppressing SR protein phosphorylation. It offers high selectivity for Clk1 and Clk4, is ATP-competitive, and is widely used in splice site selection and exon-skipping therapy research. TG003's validated action in cellular and in vivo models makes it a leading reagent for splicing modulation studies.

• Patient-Derived Gastric Cancer Assembloids Enhance Drug Test

  2026-05-19

  This study introduces a gastric cancer assembloid model that integrates matched tumor organoids with patient-derived stromal cell subpopulations, more accurately simulating tumor heterogeneity and the microenvironment. The model reveals how stromal components influence drug responses and resistance, offering a robust preclinical platform for personalized therapy optimization.

• Bradykinin as an Endothelium-Dependent Vasodilator: Applied

  2026-05-18

  Bradykinin stands out as a gold-standard endothelium-dependent vasodilator for dissecting vascular permeability, smooth muscle contraction, and pain signaling in advanced bench research. This guide delivers actionable protocols, troubleshooting solutions, and comparative insights—grounded in recent literature and APExBIO’s validated Bradykinin (BA5201)—to empower reliable, reproducible results in cardiovascular and inflammation studies.

• Caffeine in Translational Research: Mechanistic Leverage & S

  2026-05-18

  This in-depth article unpacks the multifaceted role of caffeine (1,3,7-trimethylpurine-2,6-dione) as a mechanistic probe and translational tool. By blending recent advances in cancer cell line inhibition, metabolic modulation, and integration with emerging therapeutic strategies—such as ALDH2 activation for myocardial protection—it provides actionable insights and strategic considerations for translational researchers. The discussion benchmarks caffeine against the evolving landscape of small molecule innovation, highlights protocol-critical parameters, and maps a forward-looking agenda for maximizing its value in high-impact workflows, with APExBIO’s product at the center.

• PCMT1 Identified as a Key Driver of Ovarian Cancer Metastasi

  2026-05-17

  Zhang et al. used a genome-wide CRISPR/Cas9 knockout screen to systematically identify PCMT1 as a central mediator of anoikis resistance and metastasis in ovarian cancer. Their findings elucidate how PCMT1 modulates extracellular matrix interactions and focal adhesion signaling, providing a foundation for potential therapeutic strategies targeting metastatic progression.

• Losartan Nanohydrogel Remodels Tumor Mechanics to Boost Immu

  2026-05-16

  Hou et al. (2024) developed a Losartan-based nanocomposite hydrogel that remodels the tumor mechanical microenvironment, overcoming resistance to chemo-immunotherapy. This innovation demonstrates how targeted modulation of extracellular matrix stiffness can enhance checkpoint blockade efficacy in refractory tumors.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit: Precision Pr

  2026-05-15

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit empowers researchers with a robust, customizable workflow for generating high-sensitivity fluorescent RNA probes. Its optimized chemistry enables reliable probe synthesis for advanced in situ hybridization and Northern blot applications, setting a new standard for flexibility and reproducibility.

• Capsazepine: Mechanistic Leverage in Translational Pain Rese

  2026-05-15

  This thought-leadership article explores the mechanistic underpinnings and strategic guidance for using Capsazepine—a selective TRPV1 ion channel antagonist—in translational pain and apoptosis research. Integrating recent advances in cannabinoid-mediated pain modulation, the piece frames Capsazepine as a critical tool for dissecting nociceptive pathways and guiding preclinical models toward clinical relevance. Evidence-based protocol recommendations and a comparative landscape analysis empower researchers to optimize their studies, while a forward-looking outlook contextualizes Capsazepine's impact in multi-modal pain research.

• Bestatin Hydrochloride: Applied Workflows in Tumor and Angio

  2026-05-14

  Bestatin hydrochloride (Ubenimex) offers precise inhibition of aminopeptidase N and B, uniquely enabling researchers to dissect mechanisms of tumor growth, angiogenesis, and neuronal peptide processing. This article delivers actionable guidance, advanced troubleshooting, and direct protocol enhancements for leveraging Bestatin hydrochloride in cell-based, in vivo, and neurobiology workflows.

• Cycloheximide (A8244): Precision Inhibition for Reliable Cel

  2026-05-14

  This article delivers scenario-driven, evidence-based guidance for using Cycloheximide (SKU A8244) as a protein biosynthesis inhibitor in cell viability, apoptosis, and protein turnover assays. Drawing on validated protocols, vendor comparisons, and recent research, we demonstrate how Cycloheximide addresses common laboratory challenges to ensure reproducibility and data integrity.

• CX-4945 (Silmitasertib): CK2 Inhibition Workflows in Oncolog

  2026-05-13

  CX-4945 (Silmitasertib) unlocks robust experimental workflows for CK2 inhibition, spanning both cancer research and host-targeted antiviral strategies. This guide delivers evidence-driven protocols, highlights troubleshooting insights, and distills the latest mechanistic advances—empowering researchers to bridge oncology and virology with confidence.

• Biotin-16-UTP: Precision RNA Labeling for lncRNA-Protein Stu

  2026-05-13

  Explore how Biotin-16-UTP empowers precise biotin-labeled uridine triphosphate incorporation for advanced RNA detection and purification. This deep dive uniquely connects lncRNA-protein interaction workflows with translational assay decisions, setting it apart from prior coverage.

• Biotin-16-UTP: Technical Guide for RNA Labeling Workflows

  2026-05-12

  Biotin-16-UTP is a biotin-labeled uridine triphosphate designed for robust RNA labeling during in vitro transcription. It addresses the need for sensitive, specific RNA detection and purification, particularly in RNA-protein interaction and localization studies. This product is best suited for molecular biology research workflows and should not be used for diagnostic or clinical applications.

14955 records 1/997 page Next 12345 下5页 Last page